Paper Details

  1. Home
  2. Paper Details

Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study.

Author: BerksonD M, ColferH T, CressmanM D, FarmerJ A, FarnhamD J, JonesP H, McKenneyJ M, ProctorJ D, WolfsonP M, WrightJ T

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Pravastatin, a new inhibitor of HMG-CoA reductase, effectively reduced LDL cholesterol in patients with primary hypercholesterolemia, with a dose-dependent effect. The drug was well tolerated with no treatment-related adverse events.
Paper Details　
Original Abstract of the Article :
This multicenter, double-blind, placebo-controlled study was conducted to evaluate dose-response effects and safety of once-daily administration of pravastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Pravastatin 5, 10, 20, 40 mg or placebo was administered at b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/clc.4960140211

データ提供：米国国立医学図書館（NLM）

Pravastatin: A Dose-Dependent Approach to Lowering Cholesterol

High cholesterol is a major health concern, often requiring medication to manage. This research investigates the dose-response effects of pravastatin, a commonly used cholesterol-lowering drug. The study demonstrated that pravastatin produced dose-dependent reductions in LDL cholesterol and total cholesterol levels in patients with primary hypercholesterolemia. These findings underscore the importance of finding the optimal dose of pravastatin for individual patients to achieve optimal therapeutic outcomes.

A Personalized Journey in Cholesterol Management

This research emphasizes the importance of finding the right dose of pravastatin for individual patients to effectively manage cholesterol levels. The study highlights the need for a personalized approach to cholesterol management to maximize therapeutic benefits.

A Desert Oasis of Cholesterol Control

Imagine a vast desert, where the only source of water is a small oasis. This is how I see the challenges faced by individuals with high cholesterol. This research offers a potential oasis of hope, a safe and effective way to manage cholesterol using pravastatin.

Dr. Camel's Conclusion

This research demonstrates the dose-dependent efficacy of pravastatin in lowering cholesterol levels, highlighting the importance of finding the optimal dose for individual patients.

Date :
  1. Date Completed 1991-07-12
  2. Date Revised 2019-05-10
Further Info :

Pubmed ID

1904333

DOI: Digital Object Identifier

10.1002/clc.4960140211

Related Literature

Article Analysis
・Effects of pravastatin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.